66
Participants
Start Date
December 1, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen
"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles; 1) chidamide 30mg biw × 2weeks;2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles;~1)dicitabine 25mg d1-3,2)liposome mitoxantrone 20mg d4,3)cytarabine 10mg/m2 Q12h d1-7 4)G-CSF 300ug d-1 until WBC \> 20×109/L"
RECRUITING
Bing Xu, Xiamen
Collaborators (2)
Chipscreen Biosciences, Ltd.
INDUSTRY
CSPC Pharmaceutical Group Limited
INDUSTRY
Fujian Provincial Hospital
OTHER
Fujian Cancer Hospital
OTHER_GOV
Zhangzhou manicipal hospital of Fujian Province
UNKNOWN
Jieyang People's Hospital
OTHER
Huizhou Municipal Central Hospital
OTHER
The First Affiliated Hospital of Xiamen University
OTHER